In this study, we used chronic treatment with rapamycin on TSC1/TSC2-mutant tumor cell lines, including human BLCA, HCC, and AML, and mouse RCC, to generate rapamycin-persistent (RP) derivatives. Here, TSC1 is linked to renal cell carcinoma.